OTC
GILD icon

Opera Trading Capital’s Gilead Sciences GILD Stock Holding History

Opera Trading Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,500
Closed -$240K – 120
2016
Q3 		$240K Buy
+1,500
New +$122K 0.05% 90

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Opera Trading Capital's GILD Position: Q4 2018 in Review

Opera Trading Capital sold out of Gilead Sciences (GILD) in Q4 2018, closing a stake of 3,358 shares — an estimated $259K sold.

Opera Trading Capital first reported a position in GILD in Q1 2016 and held it in 4 quarters. The position peaked at $3.58M in Q4 2016. 1,496 funds tracked by Wall St. Rank hold GILD as of Q4 2018.

  • Opera Trading Capital reported no remaining Gilead Sciences position as of Q4 2018 after selling out during the quarter.
  • Opera Trading Capital sold 3,358 Gilead Sciences shares in Q4 2018, an estimated $259K.
  • Opera Trading Capital first reported a position in Gilead Sciences in Q1 2016 and held it in 4 quarters.
  • Opera Trading Capital's Gilead Sciences position peaked at $3.58M in Q4 2016.
  • 1,496 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.